Scrip's Pharmaceutical Company League Tables 2007

Product Code SCR00016
Publication Date January 2007
Publisher Scrip Reports
Product Type Report
Pages
ISBN Number not applicable
Change currency
PDF £1,870.00 €2,252 $2,957 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Scrip's Pharmaceutical Company League Tables 2007

The biological-device sector is an exciting and rapidly evolving part of the healthcare scene. As with other sectors, such as the pharmaceutical and biotech sectors, licensing is playing an increasingly important role in new product development, and so is becoming a key "must have" skill for all companies involved in the sector.

All licensing benefits from a well thought-out, systematic approach, even when opportunities arise serendipitously. All successful licensing involves an element of luck, but the successful licensing manager will use his or her skills to ensure that any available luck is fully exploited.

This report seeks to review all the key elements of licensing in a way that will allow the reader to undertake his or her own licensing activities in a professional and competitive manner.

The report briefly reviews trends within the industry and their implications for licensing, then examines the basic structures and deal types most commonly employed within the industry. The negotiation process, starting with confidentiality, moving through to negotiation of a term sheet then a full agreement are all explained in depth, followed by a review of all the key clauses that need to be included in a licensing contract.

The report examines all the activities required to secure a successful inward licensing, including strategic issues, preparing corporate presentation material and target suitable partners, and then explains how to undertake the evaluation and due diligence of potential opportunities in a way to maximize the effective use of internal resources.

As outward licensing becomes increasingly competitive, it is vital that companies set out their opportunities in the most effective way possible.

The report explains in detail how to action successful out-licensing, including the preparation of confidential and non-confidential brochures, targeting of partners and how to make contact.

Financial considerations are discussed, including a detailed review of the parameters that effect deal values leading to how to best to set a value for the deal.

Of course the only purpose of concluding a licensing deal is to make money, and this cannot happen until the deal is signed! So the final section addresses how to manage the deal post-signature to ensure a successful outcome.

Licensing is a skill, just like science or sales, and in today's environment companies that possess this skill will have a clear competitive advantage.

Contents

  • Chapter 1 Methodolgy and Definitions
    • 1.1 What Are Scrip's Pharmaceutical Company League Tables?
    • 1.2 How Is The Data Collected?
  • Chapter 2 Leading Companies Ranked by Total Revenue
    • 2.1 Commentary
  • Chapter 3 Leading Companies Ranked by Growth in Total Revenue
    • 3.1 Commentary
  • Chapter 4 Leading Companies Ranked by Total Sales
    • 4.1 Commentary
  • Chapter 5 Leading Companies Ranked by Pharmaceutical Sales
    • 5.1 Commentary
  • Chapter 6 Leading Companies Ranked by Share of The Pharmaceutical Market
    • 6.1 Commentary
  • Chapter 7 Leading Companies Ranked by Total Opertaing Profit
    • 7.1 Commentary
  • Chapter 8 Leading Companies Ranked by Total Operating Profit Margin
    • 8.1 Commentary
  • Chapter 9 Leading Companies Ranked by Net Profit
    • 9.1 Commentary
  • Chapter 10 Leading Companies Ranked by Earnings per Share
    • 10.1 Commentary
  • Chapter 11 Leading Companies Ranked by Income per Employee
    • 11.1 Commentary
  • Chapter 12 Leading Companies Ranked by Pharmaceutical Operating Profit
    • 12.1 Commentary
  • Chapter 13 Leading Companies Ranked by Pharmaceutical Operating Profit Margin
    • 13.1 Commentary
  • Chapter 14 Leading Companies Ranked by Total R&d Expenditure
    • 14.1 Commentary
  • Chapter 15 Leading Companies Ranked by Total R&d Expenditure as A Percentage of Total Sales
    • 15.1 Commentary
  • Chapter 16 Leading Companies Ranked by Total R&d Expenditure as A Percentage of Total Revenue
    • 16.1 Commentary
  • Chapter 17 Leading Companies Ranked by Pharmaceutical R&d Expenditure
    • 17.1 Commentary
  • Chapter 18 Leading Companies Ranked by Total Capital Expenditure
    • 18.1 Commentary
  • Chapter 19 Leading Companies Ranked by Selling, General and Administrative Expenses
    • 19.1 Commentary
  • Chapter 20 Leading Companies Ranked by Total Assets
    • 20.1 Commentary
  • Chapter 21 Leading Companies Ranked by Current Assets
    • 21.1 Commentary
  • Chapter 22 Leading Companies Ranked by Working Capital
    • 22.1 Commentary
  • Chapter 23 Leading Companies Ranked by Pharmaceutical Assets
    • 23.1 Commentary
  • Chapter 24 Leading Biotechnology Companies Ranked by Total Revenue
    • 24.1 Commentary
  • Chapter 25 Leading Biotechnology Companies Ranked by R&d Expenditure
    • 25.1 Commentary
  • Chapter 26 Leading Biotechnology Companies Ranked by R&d Expenditure as A Percentage of Total Revenue
    • 26.1 Commentary
    • Appendix 1 Exchange Rates 2005 and 2006
    • Appendix 2 Mergers & Acquisitions of Note Table 2.1 Leading Companies Ranked by Total Revenue
    • Table 3.1 Leading Companies Ranked by Growth in Total Revenue
    • Table 4.1 Leading Companies Ranked by Total Sales
    • Table 5.1 Leading Companies Ranked by Pharmaceutical Sales
    • Table 6.1 Leading Companies Ranked by Share of The Pharmaceutical Market
    • Table 7.1 Leading Companies Ranked by Total Operating Profit
    • Table 8.1 Leading Companies Ranked by Total Operating Profit Margin
    • Table 9.1 Leading Companies Ranked by Net Profit
    • Table 10.1 Leading Companies Ranked by Earnings per Share
    • Table 11.1 Leading Companies Ranked by Income per Employee
    • Table 12.1 Leading Companies Ranked by Pharmaceutical Operating Profit
    • Table 13.1 Leading Companies Ranked by Pharmaceutical Operating Profit Margin
    • Table 14.1 Leading Companies Ranked by Total R&d Expenditure
    • Table 15.1 Leading Companies Ranked by Total R&d Expenditure as A Percentage of Total Sales
    • Table 16.1 Leading Companies Ranked by Total R&d Expenditure as A Percentage of Total Revenue
    • Table 17.1 Leading Companies Ranked by Pharmaceutical R&d Expenditure
    • Table 18.1 Leading Companies Ranked by Total Capital Expenditure
    • Table 19.1 Leading Companies Ranked by Selling, General and Administrative (Sg&a) Expenses
    • Table 20.1 Leading Companies Ranked by Total Assets
    • Table 21.1 Leading Companies Ranked by Current Assets
    • Table 22.1 Leading Companies Ranked by Working Capital
    • Table 23.1 Leading Companies Ranked by Pharmaceutical Assets
    • Table 24.1 Leading Biotechnology Companies Ranked by Total Revenue
    • Table 25.1 Leading Biotechnology Companies Ranked by R&d Expenditure
    • Table 26.1 Leading Biotechnology Companies Ranked by R&d Expenditure as A Percentage of Total Revenue